# REVIVE (Response to the Ebola Virus Vaccine)

> **NCT05992480** · PHASE4 · RECRUITING · sponsor: **Tulane University** · enrollment: 40 (estimated)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)

## Key facts

- **NCT ID:** NCT05992480
- **Lead sponsor:** Tulane University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05992480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05992480, "REVIVE (Response to the Ebola Virus Vaccine)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05992480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*